Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 20 tags : Fda save search
Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics
Published: 2022-12-20 (Crawled : 23:00) - biospace.com/
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: -0.18%
H: 0.61%
C: 0.38%
fda approved technology virus therapeutics
Radius Health's TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Published: 2022-12-20 (Crawled : 22:00) - biospace.com/
RDUS | $17.45 -0.85% -0.86% 380K
|
Health Technology
|
| O: -0.7%
H: 3.3%
C: 1.73%
tymlos treatment fda risk bone approval osteoporosis
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
Published: 2022-12-20 (Crawled : 17:00) - biospace.com/
SKYE | $9.17 -20.98% 27K
|
Transportation and Warehousing
|
| O: 4.8%
H: 14.5%
C: -8.4%
sbi-100 fda drug application authorization bioscience
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
Published: 2022-12-20 (Crawled : 15:00) - biospace.com/
EDSA | $4.16 -2.3% 6.2K
|
Health Technology
|
| O: 10.73%
H: 22.0%
C: 6.0%
fda drug candidate grants
Inspira™ Technologies Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission
Published: 2022-12-20 (Crawled : 15:00) - prnewswire.com
IINN | $1.91 -1.04% -1.05% 280K
|
Manufacturing
|
| O: -3.0%
H: 29.38%
C: 21.3%
fda submission
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
Published: 2022-12-20 (Crawled : 14:00) - biospace.com/
MAIA | $2.075 1.72% -0.72% 110K
|
|
| O: 13.5%
H: 0.0%
C: -10.54%
thio-101 fda expansion lung meeting trial cancer
Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: -3.83%
H: 5.88%
C: 5.27%
treatment fda submission
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:20) - biospace.com/
ALPMY | $9.2715 -1.11% 500K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | $125.06 -0.9% 0.0% 5.6M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda cancer
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:00) - prnewswire.com
ALPMY | $9.2715 -1.11% 500K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | $125.06 -0.9% 0.0% 5.6M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda license cancer
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
Published: 2022-12-20 (Crawled : 07:00) - globenewswire.com
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: 0.3%
H: 0.25%
C: -0.19%
treatment fda drug hypertension application
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.